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1,3-Butadiene is a major monomer in the rubber and plastics industry and is one ofthe highest-production
industrial chemicals in the United States. Although not highly acutely toxic to rodents, inhalation of
concentrations as low as 6.25 ppm causes tumors in mice. Butadiene is oncogenic in rats, but much higher
exposure concentrations are required than in mice. Chronic toxicity targets the gonads and hematopoetic
system. Butadiene is also a potent mutagen and clastogen. Differences in the absorption, distribution, and
elimination ofbutadiene appear to be relatively minor between rats and mice, although mice do retain more
butadiene and its metabolites after exposure to the same concentration and have a higher rate of metabolic
elimination. Recent studies have demonstrated that major species differences appear to occur in the rate of
detoxication of the primary metabolite, 3-epoxybutene (butadiene monoepoxide [BDMO]). Mice have the
greatest rateofproduction ofBDMOascomparedtootherspecies,buttherateofremovalofBDMOappearsto
be less than in otherspecies. Mice have low levels ofepoxide hydrolase; rats have intermediate levels; monkeys
and humans appear to have high levels of this detoxifying enzyme. Thus, while only low levels ofbutadiene
exposure mayresult in an accumulation ofBDMO inthe mouse, muchhigherlevelswouldberequiredtoresult
in an elevation ofcirculating BDMO in other species. The level ofthis reactive metabolite may be correlated
with the species differences in butadiene sensitivity.
Introduction
1,3-Butadiene is a colorless gas used mainly in the
production of synthetic rubber and plastics. Annual pro-
duction ofmore than 3 billion pounds in the United States
accounts for approximately one-fourth ofthe world's pro-
duction (1). Occupational exposure can occur during its
production and use, as well as during storage and trans-
port. Although such exposure is generally well below 20
ppm, much higher exposures have been reported (2).
Environmental exposure occurs due to the production of
butadiene in cigarette smoke, fossil fuel incineration, and
automotive emissions (3). Production and use ofbutadiene
resulted inthe emission of6.4 millionpoundsintothe airin
1988 (4). Low levels ofbutadiene are found in gasoline (5).
Because of the low acute toxicity, the Occupational
Safety and Health Administration (OSHA) set the per-
missible exposure limit (PEL) for butadiene at 1000 ppm
(6). However, reports of the rodent carcinogenicity of
butadienecausedtheAmerican Conference ofGovernmen-
tal Industrial Hygienists tolowerthethreshold limitvalue
(TLV) to10 ppm(7). OSHAhasrecentlyproposed lowering
the PEL to 2 ppm (8). Butadiene was identified as a
hazardous air pollutant in the 1991 reauthorization of the
Clean Air Act (9). The International Agency for Research
Health Effects Research Laboratory, U.S. Environmental Protection
Agency, MD-66, Research Triangle Park, NC 27711.
Thismanuscript waspresented atthe International Symposium onthe
Health Effects ofGasoline held 5-8 November 1991 in Miami, FL.
on Cancer (IARC) has classified butadiene as a "IIB"
carcinogen, i.e., possibly carcinogenic in humans (10); the
U.S. Environmental Protection Agency classifies it simi-
larly as a B2 carcinogen (11).
Toxicity
Acute toxicity to butadiene requires high exposure con-
centrations. Shugaev (12) reported that the LC50 in rats
after a 4-hr exposure was 129,000 ppm, whereas a con-
centration of122,000ppmresultedin 50%lethalityinmice
after only 2 hr of exposure. Exposure to 250,000 ppm for
approximately 30 min resulted in the death of exposed
rabbits (13). Exposure of men to 2000 ppm for 6-8 hr
resulted only in minor eye irritation (13).
Few adverse effects result from exposures of experi-
mental animals to concentrations below 4000 ppm. Expo-
sure ofvarious experimental animal species to 6700 ppm
for8months (7.5 hr/day, 6 days/week) revealed only amild
growth retardation and reversible liver degeneration (13).
Morerecentstudiesinratsshowedessentiallynoeffectsin
rats afterexposure for13weeks (6hr/day, 5 days/week) to
8000 ppm butadiene (14).
Developmental toxicity has been examined in both rats
and mice using a standard Segment II protocol. Studies
conducted at Battelle Northwest Laboratories (15-17)
have demonstrated that butadiene is maternally toxic to
Sprague-Dawley rats at 1000 ppm. However, there is no
developmental toxicity observed in the rat fetuses even at
doses where maternal toxicity is observed. In contrast,
both maternal and developmental toxicity is observed atL. S. BIRNBAUM
200 ppm in CD-1 mice. A reduction in the weight ofmale
mouse fetuses was also observed at 40 ppm, but no mater-
nal toxicity was evident. After exposure to 200, 1000, or
5000 ppm for 5 days, there was a concentration-related
increaseinabnormal sperminmaleB6C3F1 mice (17). The
immunotoxicity of butadiene was examined in male
B6C3F1 mice exposed to 1250ppm (6 hr/day, 5 days/week)
for 12 weeks (18). No effects were noted in either humoral
or cell-mediated immunity.
Chronic toxicity studies have been. conducted by the
National Toxicology Program (NTP) in B6C3F1 mice (19).
Testicular atrophywas noted at625ppm inmalemice, and
ovarian atrophy occurred at doses as low as 6.25 ppm in
female mice exposed for 40 weeks (6 hr/day, 5 days/week).
Bone marrowtoxicitywas also observed atthis time point
with adecrease in red blood cells, hemoglobin, andpacked
red cell volume at 2 62.5 ppm. An increase in mean cor-
puscularvolumewas noted at625ppm. These changes are
consistent with poorly regenerative anemia at doses 62.5
ppm. Earlier studies conducted by Irons and co-workers
(20) in B6C3F1 mice exposed to 1250 ppm for 6weeks had
demonstrated a macrocytic-megaloblastic anemia charac-
terized by an increase in micronuclei and leukopenia due
mainly to neutropenia. These changes may result from
interferencewithnormalbone celldifferentiation. Thereis
also some indication ofaltered hematological parameters in
humans occupationally exposed to 20 ppm butadiene (21).
Butadiene is apotentmutagenboth invivo and invitro
(22). In studiesinvolvingbacterialmutagenicity, butadiene
has been shown to be a base-pair mutagen in Salmonella
typhimurium strains TA1530 and 1535 (23). Its muta-
genicity requires metabolic activation (24). Butadiene also
causescytogeneticeffectsinthewholeanimal.Ticeand co-
workers (25) examined the effects in bone marrow after a
2-week exposure to male B6C3F1 mice (6 hr/day, 5 days/
week). Significantincreaseswerenotedinsisterchromatid
exchanges at 6.25 ppm, in circulating micronuclei at 62.5
ppm, and in chromosome aberrations at 625 ppm. Recent
studies by Goodrow et al. (26) have demonstrated that
proto-oncogenes are activated in mouse liver and lung
tumors and lymphomas after exposure to butadiene. The
activating mutation is in codon 13 ofthe K-ras oncogene, a
mutation never seen in spontaneouslyarisinglivertumors.
The inactivation of suppressor genes has also been noted
in tumors from butadiene-exposed mice (27). On-going
studies using transgenic mice have demonstrated in vivo
activation oftransgenes after butadiene exposure (28). In
vitro workinvolvingTK-6, ahuman lymphoid cell line, has
demonstrated mutation in the HGPRT locus (29).
Carcinogenicity
The carcinogenicity ofbutadiene inrats has been exam-
ined by a study conducted under the auspices of the
International Institute of Synthetic Rubber Producers.
This studywas first reported in 1981 (30) and in the peer-
reviewed literature in 1987 (31). Male andfemale Sprague-
Dawley rats, 100/group, were exposed to concentrations of
0, 1000, and 8000 ppm butadiene for 2 years (6 hr/day, 5
days/week). Butadiene caused significant increases at the
high dose in pancreatic and testicular tumors in males. In
females, significantincreases occurred atboth thelowand
high dose in mammary gland tumors and at the high dose
in thyroid gland tumors. There was also an increasing
trend observed in females for uterine and Zymbal gland
tumors. Thus, butadiene is a multisite carcinogen in both
sexes ofrats. It is important to note that survival was not
compromised at the low concentration.
The carcinogenicity ofbutadiene was examined in male
and female B6C3F1 mice, 50/group, exposed to 0, 625, or
1250 ppm butadiene for 60 (male) or 61 (female) weeks (6
hr/day, 5 days/week (32,33). The study had been intended
to last for2years, but earlymortality due to the induction
oflethal tumors resulted in study termination. For exam-
ple,by60weeks, lessthan20% ofthemales exposed tothe
high concentration and 25% exposed to the lowconcentra-
tion were still alive. Survival of the controls was greater
than 95% at this time. Malignant T-cell lymphomas were
presentinbothmales andfemales atthelowconcentration
(625ppm) andwere the cause ofearlydeath inmostcases.
These thymic lymphomas are distinct from the spon-
taneous lymphomas occurring in this strain of mouse,
which are derived from B-cells. Hemangiosarcomas ofthe
heart, an extremely rare tumor, were also found in both
sexes, aswerelungandforestomachtumors.Theincidence
of hemangiosarcomas, lymphomas, and lung tumors was
similar at the two concentrations. The decrease in for-
estomach tumors at the high concentration maywell have
been due to the excessive early mortality. In addition,
tumorswerefoundinthemammarygland, ovary, andliver
offemale mice at 1250 ppm. Thus, as in the rat, butadiene
was a multisite carcinogen in both sexes ofB6C3F1 mice,
but at significantly lower exposure concentrations.
In order to better understand better the induction of
tumors in the mouse by butadiene, a second carcino-
genicity studywas conducted by the NTP (19). This study
focused onboth dose-response relationships andtheissue
of time to tumor, with the inclusion of stop studies. Male
and female B6C3F1 mice, 70/group, were exposed to 0,
6.25,20, 62.5,200, and 625 ppmbutadiene for 40 (10 mice),
65(10mice), or103 (50mice)weeks (6hr/day,5days/week).
In addition, mice (50/group/sex) were exposed to 200 ppm
for40weeks, 625 ppm for 13weeks, 312 ppm for 52 weeks,
or 625 ppm for 26 weeks, resulting in a total exposure of
approximately 8000 or16,250ppm-weeks. As inthe earlier
study, survival was severely compromised in both sexes at
625 ppm; all the mice died before 70 weeks of exposure.
Survivalwasalsodecreased at200ppm,butthiseffectwas
much less severe as the concentration decreased. For
example, in females the thymic lymphomas led to reduced
survival at 200 ppm. The only concentration at which
survival was not affected by exposure to butadiene was
6.25 ppm.
Asintheearlierstudy,tumorsappearedatmultiplesites
in both sexes ofmice. A significant increase in malignant
tumors was detected at 20 ppm in males and 6.25 ppm in
female mice. In addition to the lymphomas, hemangiosar-
comas, and lung and forestomach tumors seen previously,
tumorswere nowobserved inthe Harderiangland, prepu-
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tial gland, and liver in males and in the Harderian gland,
liver, ovary, andmammaryglandinfemales. The detection
of these additional sites appears to be due to the disap-,
pearance of the thymic lymphomas at the low exposure
concentrations. The lymphomas are early-appearing
tumors, which can occur in less than 26 weeks after the
start ofexposure. In contrast, the hemangiosarcomas do
not appear until 40 weeks. When the concentration of
butadiene is lower, the lymphomas do not occur, allowing
for the development of malignancies in other tissues. A
similar pattern is apparent for the induction of lung
tumors, which also do not appear until approximately 40
weeks ofexposure. This tumor is the most sensitive tumor
end point in the female mouse, occurring with a statis-
tically significant increase at the lowest dose used in this
study, 6.25 ppm. Examination of the concentration-
response curves for the induction of tumors in both male
and female mice confirms the observation that the T-cell
response is a high-concentration effect. In contrast, a
linear relationship is observed between incidence and
exposure concentration for the other major tumors (lung,
Harderian gland, heart, forestomach).
Studies that maintained a constant concentration-time
relationship demonstrated that the high exposure con-
centrationwasresponsiblefortheinductionoflymphomas.
Only 13 weeks of exposure to 625 ppm resulted in a 47%
incidence ofthymic lymphomas in male mice, whereas no
significant increase occurred when mice were exposed to
200 ppm for 40 weeks. In contrast, the total exposure
(ppm-weeks) appears to determine the response in the
other tissues.
Thus, butadiene causes tumors at multiple sites in both
sexes of rats and mice. However, while tumors occur at 6
ppm in the mouse, the lowest concentration at which
tumorswerenotedinratswas at1000ppm.Theonlytumor
siteincommonbetweenthetwo specieswasthemammary
gland in the female. The rat tumors are all in endocrine
tissues. Nevertheless, butadiene is clearly a potent animal
carcinogen.
The exquisite sensitivity of the B6C3F1 mouse to
butadiene-induced tumors hasbeenhypothesized to relate
to the presence of an endogenous ecotropic retrovirus in
thesemice (34). ExposureofNIHSwissmice,whichdonot
have the retrovirus, results in a much lower lymphoma
incidence. However, these studies demonstrate that the
virus is not required for tumor induction, although it may
play amodulatoryrole. Other strain differences could also
explain the different lymphoma incidence.
Although butadiene is clearly a potent rodent carcino-
gen, the question ofits human carcinogenicity is not clear
fromepidemiological studies. Threemortalitycohortstud-
ies have been conducted (35-37). In all cases, the total
cancermortalitywas low.Althoughtherewas asignificant
increase in the standardized morality ratio (SMR) for
hematopoietic cancers, the SMRs were lower for long-
terms workers in the butadiene industry than for short-
term workers. The lymphopoietic case-control study of
Matanoski et al. (38), which was nested within the largest
of the three cohort studies, does suggest an increase in
leukemia aswell asinlymphosarcomaandotherlymphatic
tumors. However, these increases are essentially only in
the black production workers and involve very small num-
bersofworkers.Anexposure-basedcohortstudyis clearly
needed to resolve the issue of whether butadiene is a
human carcinogen.
Pharmacokinetics
The dramatic differences in species sensitivity to buta-
diene carcinogenicity, as well as the observed varying
susceptibilities for developmental toxicity end points, sug-
gest thatpharmacokinetic differences among species may
exist. Pharmacokinetic studies involve analysis of the
uptake, absorption, distribution, metabolism, and elimina-
tion ofbutadiene and its metabolites, both experimentally
and by mathematical modeling. The major approaches
used to study the pharmacokinetic behavior ofbutadiene
in experimental animals and humans have involved gas
uptake, chemical disposition, and in vitro metabolism
studies. In the early 1980s, the laboratories of Filser and
Bolt (39) pioneered the use ofclosed-chamber systems to
study the pharmacokinetics of butadiene. They placed
Sprague-Dawley rats (40) orB6C3F1 mice (41) in air-tight
chambers filled with a known concentration of butadiene
and then monitored the disappearance ofbutadiene from
the chamber. In this system, the loss ofbutadienewas due
to its uptake and metabolism by the animals. The disap-
pearance of butadiene was nonlinear at exposure con-
centrations greater than 1000 ppm, with metabolic
saturation occuring at concentrations > 1500 ppm in both
rats andmice. Themajordifferencebetweenmice andrats
was that the rate ofmetabolic elimination (Vmax) in mice
was approximately twice that ofrats. These investigators
(40) also observed that the metabolic elimination ofbuta-
diene could be blocked by pretreatment of the rats with
dithiocarb, indicating that metabolism was mediated by
the cytochrome P450 monoxygenase system. Metabolism
was also inducible by Aroclor 1254. Such pretreatment
resultedinadramaticincreaseintheVmaxandnoevidence
ofsaturation at exposure concentrations as high as 12,000
ppm butadiene.
Metabolismofbutadiene occursviaepoxidation ofone of
the double bonds to produce 1,2-epoxybutene-3, also
known as vinyl oxirane or butadiene monoepoxide
(BDMO). Malvoisen and co-workers (42) demonstrated
thatthismicrosomalreaction was NADPH dependentand
was inducible by phenobarbital but not by 3-methylchol-
anthrene. It could be inhibited by SKF525A. Such behav-
ior is characteristic of a cytochrome P450 mediated
reaction. Theproduction ofthismetabolite invivo couldbe
demonstrated in the closed-chamber system (43).
There are multiple pathways that can lead to the disap-
pearance of the monoepoxide. Malvoisen and Roberfroid
(44) used an in vitro system to demonstrate that BDMO
could be hydrated via epoxide hydrolase to form the 3,4-
dihydroxy-1,2-butene (butenediol). Usingmicrosomesfrom
Wistar rats, they observed that the Km for this pathway
wasrelativelyhigh compared to thatoftheinitial epoxida-
tion step, suggesting that the activation of butadiene to
BDMO is favored over hydration of BDMO to the diol.
163L. S. BIRNBAUM
BDMO can also serve as asubstrate for afurtherround of
epoxidation, leading to the production of diepoxybutane,
which is more highly reactive and carcinogenic than the
monoepoxide (22). Whether this metabolite is actually
produced in vivo is unsure given the lack of detection of
diepoxybutane-induced DNA crosslinks in vivo in either
rats or mice (45). Both the mono- and diepoxide can also
conjugate with glutathione, a reaction catalyzed by a sol-
uble glutathione-S-transferase. Recent studies have indi-
cated that this reaction results in detoxication (46). The
butenediol can undergo another round ofepoxidation and
hydration to form the tetrol, erythritol, which can also be
produced by action of epoxide hydrolase on the diepoxy-
butane.
The metabolic elimination ofBDMO canbefollowed in a
closed-chamber system. If rats or mice are exposed in a
closed chamber to BDMO, the disappearance ofBDMO is
linearup to 1000 ppm inrats, while saturation ofmetabolic
elimination is observed at 500 ppm in mice. In fact, in the
linearrange (<500ppm),thesteady-stateconcentration of
BDMO in mice is approximately 10 times that in rats. Rats
are abletoeliminate BDMOfasterthanmice. The Vmaxfor
metabolic elimination in rats is 8 times greater than
observedinmice(47).Thus,mice areabletogeneratemore
BDMO than rats when exposed to a similar concentration
of butadiene; rats more readily eliminate this reactive
metabolite.
The suggestion that differences in the rate ofmetabolic
elimination of butadiene and its reactive metabolite,
BDMO, could play a role in the differential species sen-
sitivityobserved hasbeen supported bya series ofstudies
ofthe disposition ofbutadiene in mice, rats, and monkeys
(48). These studies involved dynamic, nose-only exposures
to radiolabeled butadiene. The retention of the radioac-
tivityanditstissue distributionwas examined inSprague-
Dawley rats and B6C3F1 mice at multiple time points
following cessation of exposure to butadiene concentra-
tions ranging from 0.08 to 8000 ppm. The elimination of
butadiene-derived radioactivity was examined in the
exhaled air, urine, and feces after exposure. At the same
exposure concentration, mice retained more of the
butadiene-derived radioactivity than rats (49), resultingin
a higher dose. This may be due to the greater minute
volume in mice as compared to rats. However, recent
studies in cynomolgus monkeys have indicated that reten-
tioninmonkeysis similar tothatobserved inrats (50). The
disposition studies using radioactivity also indicated that
nonlinearities in metabolism were observed in the mice at
exposure concentrations above100ppm, asindicated byan
increaseinthepercentage ofradioactivityexhaled asCO2.
This shift occurred at higher concentrations in the rats in
good agreementwith the results fromthe closed-chamber
studies.
The distribution ofbutadiene-derived radioactivitywas
also examined in the tissues of mice and rats (51). Few
differenceswereobserved. Fatwasthemajortissuedepot.
Theconcentration ofradioactivityinthebloodwasgreater
in mice than in rats. This labeled material has been tenta-
tivelyidentified as butadiene monoepoxide; itis clearly not
theparent compound (48). The concentration ofbutadiene-
derived radioactivity is lowest in the blood of exposed
monkeys(50). In allthreespecies,routesofeliminationofthe
butadiene-derived radioactivity were similar, with most of
the metabolites appearing in the expired air and urine.
Although there are some differences in the uptake and
metabolic rate between rats and mice, these alone are not
sufficient to explain the dramatic differences in species
sensitivity to butadiene carcinogenesis. One possibility
that requires examination is the species differences in
metabolic pathways, as suggested by the differential abil-
ity to remove the monoepoxide observed in the closed-
chamber studies. To investigate different metabolic path-
ways aswell astheroleoftissuesotherthantheliverinthe
metabolic activation and detoxication ofbutadiene, in vitro
systems havebeenused. Malvoisenand Roberfroid (44), as
mentioned above, demonstrated thatwhenusingrat hepa-
tic microsomes, activation of butadiene was favored over
hydration ofthe monoepoxide. The critical role ofepoxide
hydrolase in the detoxication ofBDMO was demonstrated
by Bolt et al. (43), who demonstrated that incubation of
microsomeswithtrichloropropylene oxide, aspecificinhib-
itor of epoxide hydrolase, increased the levels of BDMO.
These investigators observed that addition ofglutathione
(GSH) and soluble enzymes to the microsomes resulted in
a decrease in the level ofthe monoepoxide. This ability of
GSH to detoxify BDMO was further examined using in
vivo exposures in which the depletion of glutathione was
observed to be more pronounced in mice than in either
Sprague-Dawley or Wistar rats (52). Such depletion is
often correlated with enhanced toxicity. In fact, the levels
of BDMO appear to build up once the GSH is depleted.
Deutschmann and Laib (53) demonstrated a dose-
dependent decrease in GSH concentrations starting
between 100 and 250 ppm in the mouse. Higher exposure
concentrations alsoledto depletionofGSHinthelungand
heart of the mouse. In contrast, a major reduction in
hepatic glutathione was not observed in the rat until
exposure to 2000 ppm butadiene. Few changes were
observed in the rat heart or lungs.
Butadiene can be metabolized in tissues in addition to
the liver. Bond and co-workers (54) compared the in vitro
metabolismofbutadieneinmicrosomesfromliverandlung
ofrats and mice. The rate ofbutadiene disappearance was
similar using rat and mouse liver microsomes, but
appeared to be higher in rat than in mouse lung. Recent
studies in which BDMO formation was directly measured
in vitro revealed that mouse lung microsomes activate
butadiene atratesnearly15times greaterthaninrats (55).
Lorenz and co-workers (56) also reported thatthe relative
activation of butadiene by mouse lung microsomes was
greater than that observed in rat lung, in agreementwith
studies by Schmidt and Loeser (57). In vitro hepatic
activities observed from all of these groups has been
greater in the mouse than in the rat. Pretreatment ofthe
rats and micefor 5 dayswith butadiene failed to induce its
ownmetabolism in eithertissue (54). Themetabolic rate in
ratnasalmucosaappeared similartothatobservedinliver
and lung (54). Recent studies have indicated that
myeloperoxidase-mediated metabolism of butadiene may
occur in the bone marrow (58).
164ROLE OF METABOLISM IN BUTADIENE HEALTH EFFECTS
Several investigators have attempted to compare the
rate of butadiene activation in vitro in humans with that
observedinexperimental animals. Usinglivermicrosomes
fromWistar and Sprague Dawleyrats, NMR and B6C3F1
mice, rhesus monkeys, and human liver, Schmidt and
Loeser (57) observed the following rate of formation of
BDMO: mouse > rat > man > monkey. Csanady and co-
workers (55) noted a lower rate offormation ofBDMO in
rat liver microsomes than in humans or mice. Rates of
butadiene activationinhumanlungmicrosomeswere similar
to rats (55).
The critical issue is not the rate offormation ofBDMO,
but the steady-state levels in the organism. This has not
yet been experimentally determined. However, hints at
species differences are apparent from comparison of the
relative rates for BDMO formation and its further bio-
transformation to other metabolites. As discussed above,
removal of BDMO appears to be catalyzed by two major
enzymes: epoxide hydrolase and glutathione-S-trans-
ferase. The in vivo studies suggest that rats may have
greater epoxide hydrolase activity than mice, resulting in
lower utilization of the glutathione transferase pathway,
and hence, lower probability ofcausing glutathione deple-
tion. Lorenz et al. (56) observed that although rats had
greater hepatic epoxide hydrolase activity, mice had
higher levels ofthe transferase. Csanady et al. (55) noted
that mouse liver microsomes had approximately twice the
rate ofdiol formation from BDMO than rats, but that this
was much lower than that observed in human liver micro-
somes. This isin agreementwith theearlierobservation of
Schmidt and Loeser (57) that epoxide hydrolase activity
was highest in monkeys and humans but very low in
rodents. Recent studies by Kreuzer et al. (59) noted that
the relative epoxide hydrolase activity using BDMO as a
substrate was man > rat > mouse. This relative activity
profile was reversed for glutathione-S-transferase-
catalyzed conjugation of GSH with BDMO. In fact, the
abilityofhumanlivermicrosomes toformthediolfromthe
monoepoxide was about 25 times greater than the activa-
tionofbutadiene tothemonoepoxide. Overall,theabilityof
rats to generate the monoepoxide and then eliminate it is
not as great as that of the human but better than the
mouse,whichisveryactive atactivatingbutadiene buthas
only limited ability to remove the monoepoxide.
Invivostudies examiningtheprofile ofurinarymetabo-
lites after butadiene exposure have lent support to the
hypothesis that while mice preferentially metabolize
BDMO via conjugation with glutathione, rats use this
pathway, as well as epoxide hydrolase, and monkeys favor
diol formation almostexclusively (60). Inhalation exposure
ofmonkeys to butadiene resulted in the presence of only
one major metabolite in the urine, which has been identi-
fied as the N-acetylcysteine conjugate ofbutanediol. This
metaboliteis aproductofthesequentialactivityofepoxide
hydrolase on BDMO, generating the butenediol, which
then becomes a substrate for the glutathione-S-trans-
ferase. In contrast, in mice, although there are low
amountsofthisbutenediol conjugate, themajormetabolite
is theN-acetylcysteine conjugate ofbutene-2-ol, theprod-
uct of direct conjugation of BDMO with GSH. There are
nearly equivalent amounts of the two metabolites in the
rat. Thus, in rodents the levels of circulating epoxide are
high enough to be available for conjugation with glu-
tathione, but in primates the high levels ofepoxide hydro-
lase activity ensure that the monoepoxide is rapidly
converted to the diol.
Theweight ofevidence suggests thatthe mousehas the
greatest ability to create the active metabolite of buta-
diene, BDMO, but the least capacity to remove it. While
proofofelevated steady-state levels ofBDMO has not yet
been obtained, there is additional indirect in vivo data in
support of this hypothesis. Butadiene exposure to mice
andratsresultedinapproximately2-foldhigherbindingto
nucleoproteins in mice than in rats (61). Measurement of
hydroxybutenylvaline in hemoglobin, whichis aproduct of
the reaction ofBDMO with the N-terminal valine, reveals
that mice produce more than 10 times the level of this
adduct following exposure to 2000 ppm butadiene, as do
rats (J. Bond, personal communication). Hemoglobin
adducts are a reflection of the circulating levels of the
monoepoxide; they are a function of the balance between
butadiene activation and detoxication. DNA adducts are
found after inhalation exposure only in the livers ofmice,
notrats (62).This adductwastentativelyidentified as 7-(1-
hydroxy-3-buten-2-yl)guanine (63). The generation ofthis
adductin themouse atexposure concentrations thatcause
tumors inmice butnotin rats supports the central rolefor
BDMO in butadiene carcinogenesis.
A physiologically based pharmacokinetic model was
developed by Hattis and Wasson (64) to describe the
behaviorofbutadiene.Thismodelpredictedthatbutadiene
metabolism scaledwiththegeneralmetabolicrate,ingood
agreementwiththe experimental data. Usinga Michaelis-
Menten-type equation to describe the conversion ofbuta-
diene to the monoepoxide, the model successfully pre-
dicted the observed nonlinearities inmetabolic elimination
with exposure concentrations. Extrahepatic metabolism
also appeared toplay arole inthe overall pharmacokinetic
behavior. Csanady et al. (65) have recently developed a
physiologically based pharmacokinetic model to describe
the disposition of butadiene. The model predictions pro-
vide anexcellentfittotheexperimentally determined data
using the metabolic constants determined in vitro. Fur-
ther development and validation of this model to predict
the levels of hemoglobin adducts formed from the mono-
epoxide in rodents should enable predictions concerning
the levels of such adducts in occupationally exposed
workers.
Conclusions
Differential species sensitivity has been demonstrated
not only for the carcinogenic effects of butadiene but for
thedevelopmentaleffects aswell.Themouseappears tobe
extremely sensitive to the toxic effects of this chemical.
Althoughratesofuptakeandeliminationmayplayarolein
this differential species sensitivity, it is highly unlikely
that these form the basis for the observed differences.
However, there do appear to be significant differences in
the metabolic pathways that are preferentially used
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between different species. The results to date suggestthat
the mouse has the greatest ability to activate butadiene to
the highly reactive monoepoxide BDMO; however, the
mouse has only limited ability to remove this metabolite.
Rats form less of the monoepoxide but have a greater
ability to remove it by diol formation than mice. The ratio
of activation to inactivation, i.e., the formation of mono-
epoxide versus its removal, appears to continue to
decrease when one considers primates. If steady-state
levels ofthe monoepoxide after inhalation exposure are in
fact lower in monkeys than in rats and the level in rats are
lowerthan those in mice, this mightsuggest thatmonkeys
and humans would be less sensitive to the toxic and
carcinogenic actions ofbutadiene than are rodents.
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